LakeShore Biopharma Receives Phase III Trial Approval In China For Simplified Four-Dose YSJA Rabies Vaccine Regimen; Aims To Enhance Patient Adherence And Reduce Costs While Maintaining Immunogenicity
LakeShore Biopharma Receives Phase III Trial Approval In China For Simplified Four-Dose YSJA Rabies Vaccine Regimen; Aims To Enhance Patient Adherence And Reduce Costs While Maintaining Immunogenicity
LakeShore生物公司在中國獲得第三階段臨床試驗批准,用於簡化的四劑YSJA狂犬病疫苗方案;旨在提高患者依從性,降低成本,同時保持免疫原性。
LakeShore Biopharma Receives Phase III Trial Approval In China For Simplified Four-Dose YSJA Rabies Vaccine Regimen; Aims To Enhance Patient Adherence And Reduce Costs While Maintaining Immunogenicity
LakeShore生物公司在中國獲得第三階段臨床試驗批准,用於簡化的四劑YSJA狂犬病疫苗方案;旨在提高患者依從性,降低成本,同時保持免疫原性。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。